(Q54537376)

31 May 2018

title

Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. (English)

1 reference

31 May 2018

head and neck squamous cell carcinoma

main subject

0 references

author name string

Shoude Zhang

1

1 reference

31 May 2018

Jia Chen

2

1 reference

31 May 2018

Hua Jiang

3

1 reference

31 May 2018

Haina Ma

4

1 reference

31 May 2018

Beibei Yang

5

1 reference

31 May 2018

publication date

10 January 2012

1 reference

31 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

31 May 2018

volume

68

1 reference

31 May 2018

issue

5

1 reference

31 May 2018

page(s)

561-569

1 reference

31 May 2018

https://scigraph.springernature.com/pub.10.1007/s00228-011-1194-1

exact match

0 references

cites work

Expanding role of the medical oncologist in the management of head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Current status of experimental therapeutics for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Pharmacotherapy for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

The chemoradiation paradigm in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Molecular targeted therapies in head and neck cancer--an update of recent developments-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Targeted therapies in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Aggregate data meta-analysis with time-to-event outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Epidermal growth factor receptor inhibitors in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Gefitinib does not increase survival in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

EGFR mutations and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Epidermal growth factor receptor mutations in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Mechanisms of resistance to EGFR inhibitors in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Mechanisms of cutaneous toxicities to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1194-1

Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

12 December 2020

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

1 reference

12 December 2020

EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis

1 reference

12 December 2020

Common side effects of anti-EGFR therapy: acneform rash

1 reference

12 December 2020

Endpoints for assessing drug activity in clinical trials

1 reference

12 December 2020

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial

1 reference

12 December 2020

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S00228-011-1194-1

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018